In the CNS group, seroprevalence for anti-SSA/Ro was higher leading to a definitive diagnosis of pSS [85/173 (49.1%) vs. 15/19 (78.9%), p = 0.016], while the control group had more seronegative patients requiring a salivary gland biopsy (SGB) for their pSS diagnosis [73/159 (45.9%) vs. 3/19 (15.8%), p = 0.014]. This evidence concerns the gene CALR and peeling skin syndrome.